PharmaIN to Present Promising Interim Data from its Ongoing Phase 1 Trial of PHIN-214, an Optimized Vasopressor for Decompensated Cirrhosis, at The Liver Meeting® 2024

Press Release October 16, 2024 PharmaIN Corporation is set to present promising data from its ongoing Phase 1 trial of PHIN-214, an optimized vasopressor therapy for decompensated cirrhosis, at The Liver Meeting® 2024. BOTHELL, Wash. , Oct. 16, 2024 — PharmaIN Corporation, a clinical-stage biopharmaceutical company dedicated to developing innovative subcutaneous peptide therapies, today announced the company will present interim results from its ongoing Phase 1 clinical trial of PHIN-214, the company’s lead candidate, for the prevention and treatment of decompensated cirrhosis. Douglas Simonetto , M.D., Mayo Clinic College of Medicine and Science, Rochester, MN will present the findings at the American Association for the study of Liver Diseases (AASLD), The Liver Meeting®, taking place on November 15-19, 2024 , in San Diego, CA. PHIN-214 is an optimized vasopressor therapy targeting a clinically validated mechanism of action enabling safe, subcutaneous administration and broad application for the prevention and treatment of decompensated cirrhosis. PharmaIN is currently enrolling patients in its ongoing Phase 1 clinical trial evaluating PHIN-214 in cirrhosis ( NCT05490888 ). Presentation Details: Abstract Title: PHIN-214: Phase 1 study in compensated and decompensated cirrhosis patients – a novel treatment to manage complications of portal hypertension with subcutaneous, once-daily self-administration. Authors: Douglas A. Simonetto , MD (1), Naim Alkhouri , MD (2), Ethan Weinberg , MD, MS (3), Philipp Schwabl , MD, PhD (4), Anita Kohli , MD (2), Michael Porayko , MD (5), Eric Lawitz , MD (6) (1) Mayo Clinic College of Medicine and Science, Rochester, MN ; (2) Arizona Liver Health, Chandler, AZ ; (3) University of Pennsylvania , Philadelphia, PA ; (4) Medical University of Vienna , Vienna, Austria ; (5) Vanderbilt University , Nashville, TN ; (6) Texas Liver Institute, San Antonio, TX Abstract Number: 2173 Session: Poster, Portal Hypertension and Other Complications of Cirrhosis Date & time: Monday November 18, 2024 , 8:00 AM-5:00 PM Pacific time Location: Poster Hall Abstract titles are now available on the AASLD website. Posters will be made available on the PharmaIN website following presentation at the conference. About PharmaIN: PharmaIN Corporation is a clinical stage biopharmaceutical company dedicated to developing first- and best-in-class subcutaneous therapies through its proprietary peptide engineering platform. Through the company’s expertise in target-specific biology, peptide drug design and innovative drug delivery, PharmaIN is developing novel treatments for patients with advanced cirrhosis and cancer. To learn more, visit us at www.pharmain.com . For partnership opportunities, please contact: [email protected] Media Contact Akiko Nishimoto-Ashfield , PharmaIN Corp., 1 2065681450 *103, [email protected] , www.pharmain.com SOURCE PharmaIN Corp.

The release as fetched from its publisher. pharmain.com ↗